1Gertz MA,Lacy MQ,Dipenzier A. Immunoglobulin light chain amyloidosis and the kidney[J].Kidney International,2003.1-9.
2郑法雷;高瑞通.淀粉样变的多系统病变[A]北京:人民军医出版社,2005546-559.
3von Hutten H,Mihatsch M,Lobeck H. Prevalence and origin of amyloid in kidney biopsies[J].American Journal of Surgical Pathology,2009.1198-1205.
4Basnayake K,Stringer SJ,Hutchison CA. The biology of immunoglobulin free light chains and kidney injury[J].Kidney International,2011.1289-1301.doi:10.1016/j.jpsychires.2008.12.004.
5Kyle RA,Gertz MA,Greipp PR. A trial of three regiments for primary amyloidosis:colchine alone,melphalan and prednisone,and melphalan,prednisone,and colchine[J].New England Journal of Medicine,1997.1202-1208.doi:10.1056/NEJM199704243361702.
6Sanchrawala V,Wright DG,Seldin DC. An overview of the high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis[J].Bone Marrow Transplantation,2001.637-642.
7Dispenzieri A,Lacy MQ,Kyle RA. Eligibility for hemaopoietic stem-cell transplantation for primary systemic amyloidosis is a fevorable prognostic factor for survival[J].Journal of Clinical Oncology,2001.3350-3356.doi:10.1109/TWC.2011.031611.100309.
8Jaccard C,Moreau P,Leblond V. High-dose mephalan versus mephalen plus dexamethasone for amyloidosis[J].New England Journal of Medicine,2007.1083-1093.doi:10.1056/NEJMoa070484.
9Kumar S,Gertz MA,Lacy MQ. Recent improvement in survival in primary systemic amyloidosis and importance of an early mortality risk score[J].Mayo Clinic Proceeding,2011.12-18.doi:10.1111/j.1524-4741.2009.00875.x.
